REFERENCES
- Feng Y, Broder CC, Kennedy PE, et al. HIV-1 entry cofac-tor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996;272:872–877.
- Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996; 381:661–666.
- Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptors accounts for resistance of some multi-ply-exposed individuals to HIV-1 infection. Cell. 1996;86:367–377.
- Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science. 1996;273(5283): 1856–1862. Erratum in: Science. 1996;274(5290)1 069.
- Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med. 1996;11:1240–1243.
- O'Brien SJ, Moore JP. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev. 2000;177:99–111.
- Briggs DR, Tuttle DL, Sleasman JW, Goodenow MM. Enve-lope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). AIDS. 2000;14:2937–2939.
- Choe H, Farzan M, Sun Y, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 1996;85:1135–1148.
- Este JA, Cabrera C, Blanco J, et al. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phe-notype by blockade of CXCR4. J Virol 1999;73:5577–5585.
- Lalezari J. A novel CCR5 antagonist: antiviral activity and safety during short-term monotherapy in HIV-infected adults. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004; Washington, DC. Abstract H–1137b.
- Demarest J, Bonny T, Vavro C, et al. 873140 exhibits potent antiviral activity against a broad panel of HIV-1 envelopes from treatment naïve and experienced subjects. In: Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment; 2005; Rio de Janeiro, Brazil. Abstract TuPe6.1613.
- Sparks S, Adkinson K, Shachoy-Clark, et al. Prolonged duration of CCR5 occupancy by 873140 in HIV-negative and HIV-positive subjects. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infec-tions; 2005; Boston, MA. Abstract 77.
- Adkinson K, Shachoy-Clark A, Fang I, et al. The pharmaco-kinetic interaction between the CCR5 antagonist 873140 and Lopinavir/Ritonavir in healthy subjects. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; 2005; Boston, MA. Abstract 664.
- Fatkenheuer G, Pozniak AL, Johnson M, et al. Evaluation of dosing frequency and food effect on viral load reduction during short-term monotherapy with UK-427,857 a novel CCR5 antagonist. In: Program and abstracts of the 15th International AIDS Conference; 2004; Bangkok, Thailand. Abstract TuPeB4489.
- McHale M, Abel S, Russell D, et al. Overview of phase 1 and 2a safety and efficacy data of maraviroc (UK-427,857). In: Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment; 2005; Rio de Janeiro, Brazil. Abstract Tuoa0204.
- Muirhead G, Pozniak A, Gazzard B, et al. A novel probe drug interaction study to investigate the effect of selected ARV combinations on the pharmacokinetics of a single oral dose of UK-427,857 in HIV+ ve subjects. In: Program and abstracts of the 12th Conference on Retroviruses and Op-portunistic Infections; 2005; Boston, MA. Abstract 663.
- Schuermann D, Pechardscheck C, Rouzier R, et al. SCH 417690: antiviral activity of a potent new CCR5 receptor antagonist. In: Program and abstracts of the 3rd IAS Con-ference on HIV Pathogenesis and Treatment; 2005; Rio de Janeiro, Brazil. Abstract Tu0a0205.
- Saltzman M, Rosenberg M, Kraan M, et al. Pharmacokinet-ics of SCH 417690 administered alone or in combination with ritonavir or lopinavir/ritonavir. In: Program and ab-stracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment; 2005; Rio de Janeiro, Brazil. Abstract TuPe3.1605.
- Moyle G, Lalezari J. Blocking viral entry. J Viral Entry. 2005;1(1):2–3.
- Trkola A, Kuhmann SE, Strizki JM, et al. HIV-1 escape from a small molecule, CCR5 specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sc/ USA. 2002;99:395–400.